Ocular Therapeutix подтвердила подачу заявки на препарат AXPAXLI для лечения возрастной макулодистрофии в четвертом квартале 2026 года

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the FDA effectively signed off on during a Type C meeting held in May. That timeline, paired with new data suggesting patients could need far fewer injections, is the headline. The rest of the report shows what it costs to get there. The FDA Clears A Lane AXPAXLI’s case rests on the SOL-1 trial, which Ocular describes as the first successful superiority study of a new agent against an approved anti-VEGF therapy since that drug class arrived two decades ago. The FDA’s May 2026 meeting minutes confirmed that SOL-1’s efficacy and safety data, along with an interim safety look at the SOL-R trial and supporting evidence on axitinib, will be enough to support the NDA filing, and Ocular plans to file under the 505(b)(2) pathway, which could shave up to 60 days off a standard review. A post hoc analysis of SOL-1 adds a practical argument for the drug: applying SOL-R’s stricter rescue criteria, Ocular estimates patients could need up to 72% fewer injections through 60 weeks, or 56% once the two loading doses are counted, than a patient on a typical every-eight-week aflibercept regimen, a gap that matters given that up to 40% of wet AMD patients quit treatment within their first year. Early market research backs that pitch: about 80% of surveyed retina specialists said they would likely prescribe a drug with AXPAXLI’s profile, and more than 90% expect to adopt it within a year of approval. The company says every Tier 1 payer it has engaged, across Medicare Advantage and commercial plans, has floated premium pricing for a more durable option. Underpinning all of it is a cash balance of $598.6 million as of June 30, which management expects to last into 2028. The Spending Keeps Climbing Getting AXPAXLI to market is expensive, and the quarter showed it. Research and development spending rose to $54.1 million from $51.1 million a year earlier, selling and marketing costs climbed to $17.3 million from $13.7 million, and general and administrative expenses jumped to $22.2 million from $14.3 million, all tied to trial costs and a growing commercial team ahead of a launch that still is not approved. Net loss widened to $78.8 million from $67.8 million in the same quarter of 2025. Cash and equivalents fell from about $737.1 million at the end of 2025 to $598.6 million by June 30, and management has said its runway estimate does not yet include the full expense load a real AXPAXLI launch would require. Shares outstanding have also grown, from about 215.9 million at the end of 2025 to approximately 225.0 million by July 31, adding further dilution. Meanwhile, the SOL-R trial’s efficacy readout is now expected in the first quarter of 2028, meaning shareholders will wait longer for that dataset even as the NDA process moves ahead without it. What Traders Are Watching 49 hedge funds held Ocular Therapeutix shares in the most recent quarter, up from 46 the quarter before, a modest gain in institutional interest. Short sellers have positioned themselves in about 15.32% of the tradable float, a level that points to a real bear camp still betting against the stock. That mix of rising fund ownership and heavy short interest suggests the market has not settled on a single story here. The Next Few Quarters Ocular Therapeutix has built an unusual regulatory setup, walking into an NDA filing with the FDA’s own meeting minutes as backup and trial data pointing to a real cut in how often wet AMD patients would need treatment. Whether that translates into a re-rated stock still hinges on execution: the fourth quarter filing has to happen on schedule, and the review that follows has to move as quickly as the 505(b)(2) pathway promises. READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.